431 related articles for article (PubMed ID: 33510643)
1. Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson's Disease.
Dos Santos Pereira M; Abreu GHD; Rocca J; Hamadat S; Raisman-Vozari R; Michel PP; Del Bel E
Front Pharmacol; 2020; 11():617085. PubMed ID: 33510643
[TBL] [Abstract][Full Text] [Related]
2. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
3. Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice.
Huang YT; Chen YW; Lin TY; Chen JC
Neurobiol Dis; 2024 Apr; 193():106452. PubMed ID: 38401650
[TBL] [Abstract][Full Text] [Related]
4. Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.
Pisanu A; Boi L; Mulas G; Spiga S; Fenu S; Carta AR
J Neural Transm (Vienna); 2018 Aug; 125(8):1287-1297. PubMed ID: 29541852
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BET Protein Function Suppressed the Overactivation of the Canonical NF-κB Signaling Pathway in 6-OHDA-Lesioned Rat Model of Levodopa-Induced Dyskinesia.
Wan Y; Han L; Rong L; Yang S; Song L; Wu N; Liu Z; Gan J
Front Neurosci; 2022; 16():896322. PubMed ID: 35801173
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
7. Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway.
Yan A; Song L; Zhang Y; Wang X; Liu Z
Front Aging Neurosci; 2020; 12():625166. PubMed ID: 33597857
[No Abstract] [Full Text] [Related]
8. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
9. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
10. Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
Speck AE; Schamne MG; S Aguiar A; Cunha RA; Prediger RD
Mol Neurobiol; 2019 Apr; 56(4):2944-2951. PubMed ID: 30073506
[TBL] [Abstract][Full Text] [Related]
11. l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?
Carta AR; Mulas G; Bortolanza M; Duarte T; Pillai E; Fisone G; Vozari RR; Del-Bel E
Eur J Neurosci; 2017 Jan; 45(1):73-91. PubMed ID: 27859864
[TBL] [Abstract][Full Text] [Related]
12. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
Bortolanza M; Cavalcanti-Kiwiatkoski R; Padovan-Neto FE; da-Silva CA; Mitkovski M; Raisman-Vozari R; Del-Bel E
Neurobiol Dis; 2015 Jan; 73():377-87. PubMed ID: 25447229
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Muñoz A; Garrido-Gil P; Dominguez-Meijide A; Labandeira-Garcia JL
Exp Neurol; 2014 Nov; 261():720-32. PubMed ID: 25160895
[TBL] [Abstract][Full Text] [Related]
14. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
[TBL] [Abstract][Full Text] [Related]
15. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model.
Dos Santos Pereira M; do Nascimento GC; Bortolanza M; Michel PP; Raisman-Vozari R; Del Bel E
Front Pharmacol; 2022; 13():1045465. PubMed ID: 36506543
[TBL] [Abstract][Full Text] [Related]
17. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
[TBL] [Abstract][Full Text] [Related]
18. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease.
Wan Y; Wu N; Song L; Wang X; Liu Z; Yuan W; Gan J
Front Aging Neurosci; 2017; 9():331. PubMed ID: 29093677
[No Abstract] [Full Text] [Related]
19. Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for L-DOPA-induced dyskinesia.
Alcacer C; Charbonnier-Beaupel F; Corvol JC; Girault JA; Hervé D
Neurosci Lett; 2014 Nov; 583():76-80. PubMed ID: 25233866
[TBL] [Abstract][Full Text] [Related]
20. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
